HR+/HER2-NEGATIVE BREAST CANCER
Clinical trials for HR+/HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug TOS-358 targets Hard-to-Treat breast cancer in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called TOS-358 in women with advanced HR+ HER2- breast cancer that has a specific mutation in the PIK3CA gene. The study aims to find the safest dose and see if the drug works alone or with standard treatments like fulvestrant and CDK4/6 in…
Matched conditions: HR+/HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Totus Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New triple therapy aims to control advanced breast cancer with fewer side effects
Disease control Recruiting nowThis study tests a new drug, evexomostat, added to two standard treatments for a common type of advanced breast cancer (HR+, HER2-). The goal is to see if the triple combination is safe and can reduce high blood sugar side effects often caused by the standard drugs. About 52 adul…
Matched conditions: HR+/HER2-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: SynDevRx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called MBRC-201 in people with advanced solid tumors (prostate, breast, colorectal, lung, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly …
Matched conditions: HR+/HER2-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: MBrace Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new drug called Sapu003, given with or without exemestane, in adults with advanced cancers that respond to mTOR pathways—including certain breast, kidney, liver, and neuroendocrine tumors. The main goal is to find the safest dose and check for side …
Matched conditions: HR+/HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: SAPU NANO (US) LLC • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Radioactive injection targets Hard-to-Treat pancreatic tumors
Disease control Recruiting nowThis early-phase trial is testing a radioactive drug called 177Lu-CTR-FAPI in 4 people with advanced pancreatic cancer that has not responded to standard treatments. The drug is given intravenously every 6 weeks for up to 4 doses. Researchers are checking for safety, how much rad…
Matched conditions: HR+/HER2-NEGATIVE BREAST CANCER
Phase: EARLY_PHASE1 • Sponsor: Yan Xing • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC